Last updated on January 2019

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)


Brief description of study

Patient will receive either one infusion of rituximab IV and seven administrations of rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm).

The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of administration could:

  • optimize rituximab exposure leading to improve response rate
  • increase adaptative response and then improve long-term control disease.

Clinical Study Identifier: NCT02303119

Find a site near you

Start Over

IUCT Oncopole

Toulouse, France
  Connect »

CH de Valenciennes

Valenciennes, France
  Connect »

CH D partemental Vend e

La Roche sur Yon, France
  Connect »

Clinique du Parc

Castelnau Le Lez, France
  Connect »

CH de Pays d'Aix

Aix En Provence, France
  Connect »

CH de Chamb ry

Chambéry, France
  Connect »

CHU Angers

Angers, France
  Connect »

Chu Estaing

Clermont Ferrand, France
  Connect »

H pital St Louis

La Rochelle, France
  Connect »

H pital Saint-Eloi

Montpellier, France
  Connect »

CHU Lyon Sud

Pierre Benite, France
  Connect »

CH Ren Dubos

Pontoise, France
  Connect »

CHU Nancy - H pital de Brabois

Vandoeuvre-les-Nancy, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.